HemaSphere
(Jun 2022)
P473: DEVELOPMENT OF POTENTIAL BIOMARKERS FOR IRAK4 INHIBITOR EMAVUSERTIB IN HUMAN ACUTE MYELOID LEUKEMIA
- A. Ugolkov,
- M. Pilichowska,
- C.-C. Li,
- R. C. Hok,
- M. Samson,
- M. Lane,
- R. Von Roemeling,
- R. Martell
Affiliations
- A. Ugolkov
- 1 Curis, Inc., Lexington, MA
- M. Pilichowska
- 2 Tufts Medical Center, Boston, MA, United States of America
- C.-C. Li
- 1 Curis, Inc., Lexington, MA
- R. C. Hok
- 1 Curis, Inc., Lexington, MA
- M. Samson
- 1 Curis, Inc., Lexington, MA
- M. Lane
- 1 Curis, Inc., Lexington, MA
- R. Von Roemeling
- 1 Curis, Inc., Lexington, MA
- R. Martell
- 1 Curis, Inc., Lexington, MA
- DOI
-
https://doi.org/10.1097/01.HS9.0000844780.60464.3e
- Journal volume & issue
-
Vol. 6
pp.
372
– 373
WeChat QR code